Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | The future of AML therapy

Andreas Burchert • 3 Jan 2019
ASH 2018
Acute Myeloid Leukemia Leukemia Sorafenib
SORMAIN

Andreas Burchert, MD, of the University of Marburg, Marburg, Germany, speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., reveals that chemotherapy remains the standard of care for acute myeloid leukemia (AML), before introducing the transition from chemotherapy to molecular target therapies as the future of AML treatment. Prof. Burchert also talks about SORMAIN trial, utilizing molecular therapy to improve the outlook for patients with FLT3-ITD-positive AML.

More from Andreas Burchert

5:07
Optimizing transplantation outcomes for patients with AML
Andreas Burchert • 15 Oct 2021
5:00
Post-transplant maintenance strategies in AML
Andreas Burchert • 15 Oct 2021
2:57
Sorafenib as SOC maintenance after allo-transplant in FLT3+ AML
Andreas Burchert • 15 Oct 2021
2:23
Sorafenib for FLT3-ITD-positive AML
Andreas Burchert • 3 Dec 2018

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals